Pressmeddelanden
PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today shares tha...
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today announces...
REG
MAR
PILA PHARMA: PRECLINICAL STUDIES OF XEN-D0501 IN OBESITY INITIATED
PILA PHARMA AB (publ) (FN STO: PILA) today announces that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of...
PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER
PILA PHARMA AB (publ) (FN STO: PILA) informs that Professor Thomas Lutz DVM, PhD, University of Zurich, Switzerland is now joining PILA PHARMA's Scientific Advisory Board.
PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, informs of its p...
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
Rapporter
Video
Finansiell kalender
Om PILA PHARMA
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs 2,03 SEK (2026-01-02)
Förändring −49,12% (2025-01-02)